SEC Tracker
Get the app

Supernus Pharmaceuticals SUPN

Supernus Pharmaceuticals delists after merger

S-8 POS filing

Form
S-8 POS
Filed
Importance
Routine
  1. 1.5401 shares of Indivior common stock per Supernus share
  2. Merger completed on November 2, 2026
  3. Company becomes subsidiary of Indivior
  4. Deregistration of all unissued and unsold shares

Written from the S-8 POS on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Supernus Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Sarepta Therapeutics SRPT public float $1.7B, Jun 30, 2025
  2. Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
  3. Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
  4. Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
  5. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025